UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL				
OMB Number:	3235-028			

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

37 Estimated average burden hours per response... 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)  1. Name and Address of Reporting Person* Pearce Tillman  (Last) (First) (Middle)  C/O THRESHOLD PHARMACEUTICALS, INC., 170 HARBOR WAY, SUITE 300			2. Issuer Name and Ticker or Trading Symbol THRESHOLD PHARMACEUTICALS INC [THLD] 3. Date of Earliest Transaction (Month/Day/Year) 05/16/2014						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner X Officer (give title below) Other (specify below)						
										Chief I	Medical Office	•			
(Street) SOUTH SAN FRANCISCO, CA 94080			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line)  _X_Form filed by One Reporting Person  _Form filed by More than One Reporting Person						
(City) (State) (Zip)			Table I - Non-Derivative Securities Acqu					es Acquire	nired, Disposed of, or Beneficially Owned						
1.Title of S (Instr. 3)	ecurity		2. Transaction Date (Month/Day/Year		eemed tion Date	if Co	(Instr. 8)		Securities Acq A) or Disposed of Instr. 3, 4 and 5)	of (D) Owned Follow Transaction(s)			O Fe	wnership orm:	. Nature f Indirect Beneficial Ownership
				(Mont	th/Day/Year)		Code	VA	(A) or (D)	ì	(Instr. 3 and 4)		or (I)	Indirect (In	
Reminder:	Teport on a c	•						in this f	s who respon form are not re ntly valid OME	equired to	respond u				474 (9-02
Keminder:	inciport on a c						Acquire	in this f a curre	orm are not r	equired to B control eficially Ov	respond u number.				474 (9-02
1. Title of	·	3. Transaction Date (Month/Day/Year)	Table II  3A. Deemed Execution Date, if	4. Transact	stion Deri Secu Acquor D (D) (Inst	warra umber vative rities nired (A isposed	Acquire onts, op of 6. Ex	in this f a currer red, Dispo ptions, co	orm are not rently valid OME  osed of, or Bene nvertible secur reisable and Date	equired to B control eficially Ov ities)	o respond unumber.  wned  d Amount ying	8. Price of	9. Number of Derivative Securities Beneficially Owned Following Reported	10. Ownershi Form of Derivativ Security: Direct (D or Indirec	Benefic Owner (Instr. 4
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	Date	Table II  3A. Deemed Execution Date, if any	4. Transact	sts, calls, 5. N Deri Secu Acqu or D (D) (Inst and	warra umber vative rities nired (A isposed r. 3, 4,	Acquires, op of 6. Ex (MA) d of Da	red, Disponentions, control Date Executions 1	orm are not rently valid OME osed of, or Bene nvertible secur recisable and Date y/Year)  Expiration	equired to B control eficially Ovities)  7. Title ar of Underly Securities	o respond unumber.  wned  d Amount ying	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following	10. Ownershi Form of Derivativ Security: Direct (D or Indirec	11. Nat p of India Benefic Owners (Instr. 4

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Pearce Tillman C/O THRESHOLD PHARMACEUTICALS, INC. 170 HARBOR WAY, SUITE 300 SOUTH SAN FRANCISCO, CA 94080			Chief Medical Officer			

## **Signatures**

/s/ Tillman Pearce	05/16/2014
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests in 48 equal monthly installments over a four-year period beginning on the date of grant of May 16, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Know all by these presents, that the undersigned hereby makes, constitutes and appoints Joel A. Fernandes and Harold E. Selick, Ph.D. as the undersigned's true and lawful attorneys-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to:

- (1) prepare, execute, acknowledge, deliver and file Forms 3, 4, and 5 (including any amendments thereto) with respect to the securities of Threshold Pharmaceuticals, Inc., a Delaware corporation (the "Company"), with the SEC, any national securities exchanges and the Company, as considered necessary or advisable under Section 16(a) of the Exchange Act and the rules and regulations promulgated thereunder, as amended from time to time;
- (2) seek or obtain, as the undersigned's representatives and on the undersigned's behalf, information on transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and
- (3) perform any and all other acts which in the discretion of each such attorney-in-fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

The undersigned acknowledges that:

- (1) this Power of Attorney authorizes, but does not require, such attorneys-in-fact to act in their discretion on information provided to such attorneys-in-fact without independent verification of such information;
- (2) any documents prepared and/or executed by each such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney will be in such form and will contain such information and disclosure as each such attorney-in-fact, in his or her discretion, deems necessary or desirable;
- (3) neither the Company nor any such attorney-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and
- (4) this Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including without limitation the reporting requirements under Section 16 of the Exchange Act.

The undersigned hereby gives and grants the foregoing attorneys-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that each such attorney-in-fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney.

This Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to such attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 16th day of May, 2014.

/s/ Tillman Pearce

Tillman Pearce, M.D.